FORXIGA TABLET

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

DAPAGLIFLOZIN (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE)

Предлага се от:

ASTRAZENECA CANADA INC

АТС код:

A10BK01

INN (Международно Name):

DAPAGLIFLOZIN

дозиране:

10MG

Лекарствена форма:

TABLET

Композиция:

DAPAGLIFLOZIN (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE) 10MG

Начин на приложение:

ORAL

Броя в опаковка:

30

Вид предписание :

Prescription

Терапевтична област:

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors

Каталог на резюме:

Active ingredient group (AIG) number: 0156370002; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2014-12-12

Данни за продукта

FORXIGA (dapagliflozin propanediol monohydrate)
Page 1 of 80
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
FORXIGA
®
Dapagliflozin propanediol monohydrate
Tablets, 5 mg and 10 mg, Oral
ATC Code: A10BK01
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
AstraZeneca Canada Inc.
1004 Middlegate Road
Mississauga, Ontario
L4Y 1M4
www.astrazeneca.ca
Date of Initial Authorization:
Dec 10, 2014
Date of Revision:
Oct 10, 2023
Submission Control Number: 268982
FORXIGA
®
is a registered trademark of AstraZeneca AB, used under license by
AstraZeneca Canada Inc.
FORXIGA (dapagliflozin propanediol monohydrate)
Page 2 of 80
RECENT MAJOR LABEL CHANGES
1 INDICATIONS
10/2023
2 CONTRAINDICATIONS
08/2021
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations
08/2021
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage
Adjustment
10/2023
7 WARNINGS AND PRECAUTIONS
08/2021
7 WARNINGS AND PRECAUTIONS, 7.1.4 Geriatrics
10/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
........................................................................................................
2
TABLE OF CONTENTS
..........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................................................
4
1
INDICATIONS
.........................................................................................................................
4
1.1
Pediatrics
.............................................................................................................................
4
1.2
Geriatrics
.............................................................................................................................
5
2
CONTRAINDICATIONS
............................................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX